Stratos Wealth Partners LTD. Sells 42,972 Shares of Global X Genomics & Biotechnology ETF $GNOM

Stratos Wealth Partners LTD. lowered its holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 74.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,582 shares of the company’s stock after selling 42,972 shares during the period. Stratos Wealth Partners LTD. owned approximately 1.20% of Global X Genomics & Biotechnology ETF worth $566,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Atria Investments Inc raised its position in shares of Global X Genomics & Biotechnology ETF by 12.6% in the second quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock valued at $156,000 after buying an additional 2,073 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Global X Genomics & Biotechnology ETF by 30.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after acquiring an additional 4,615 shares during the period. Creative Financial Designs Inc. ADV raised its holdings in Global X Genomics & Biotechnology ETF by 86.7% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 22,301 shares of the company’s stock valued at $188,000 after acquiring an additional 10,358 shares in the last quarter. Sei Investments Co. raised its holdings in Global X Genomics & Biotechnology ETF by 110.4% in the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after acquiring an additional 12,105 shares in the last quarter. Finally, Insight Advisors LLC PA lifted its position in shares of Global X Genomics & Biotechnology ETF by 47.9% during the 2nd quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock valued at $503,000 after acquiring an additional 19,319 shares during the period. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of NASDAQ GNOM opened at $46.32 on Wednesday. The stock has a market capitalization of $50.49 million, a P/E ratio of -19.79 and a beta of 1.22. The stock’s fifty day moving average is $47.20 and its 200 day moving average is $42.88. Global X Genomics & Biotechnology ETF has a 52 week low of $27.20 and a 52 week high of $51.42.

Global X Genomics & Biotechnology ETF Announces Dividend

The company also recently announced a dividend, which was paid on Wednesday, January 7th. Stockholders of record on Tuesday, December 30th were given a $0.5912 dividend. The ex-dividend date was Tuesday, December 30th. This represents a dividend yield of 259.0%. Global X Genomics & Biotechnology ETF’s payout ratio is presently -26.50%.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.